Rezex RKP-Potassium K⁺ (8%) is an ion-exclusion HPLC column designed for the analysis of glyphosate, using potassium form chemistry and an 8% cross-linked resin for reliable separations.
Phenomenex Gemini C18 HPLC Columns
Gemini C18 is a robust reversed-phase HPLC stationary phase offering unique selectivity, high structural integrity, and increased loadability, making it ideal for preparative and purification applications.
Phenomenex Gemini NX-C18 HPLC Columns
Gemini NX-C18 is a rugged, high-efficiency reversed-phase HPLC column delivering controlled selectivity for ionizable compounds and reliable performance across high and low pH LC/MS workflows.
Phenomenex Gemini C8(3) HPLC Columns
Gemini C8(3) purification media is optimized for human insulin and its analogues, offering exceptional mechanical strength, high packing efficiency, and enhanced resistance to caustic regeneration conditions.
Phenomenex Gemini C6-Phenyl HPLC Columns
Gemini C6-Phenyl HPLC phase provides aromatic selectivity with low bleed performance, making it ideal for LC/MS analysis of aromatic, polar, and basic compounds under high pH conditions.
Rezex RCM-Monosaccharide Ca²⁺ (8%) HPLC column (300 × 7.8 mm) enables separation of monosaccharides, sugar alcohols, and saccharides with easy regeneration and USP L19 compliance.
Phenomenex Lux Cellulose-1 Chiral HPLC Columns
Phenomenex Lux Cellulose-1 chiral HPLC column offers reliable enantiomer separation, matching or exceeding CHIRALCEL® OD® performance across multiple modes.
Phenomenex Lux Cellulose-2 Chiral HPLC Columns
Phenomenex Lux Cellulose-2 chiral HPLC column, a halogenated cellulose phase, ensures superior enantiomer separation and is a proven alternative to CHIRALCEL® OZ®.
Phenomenex Lux Cellulose-3 Chiral HPLC Columns
Phenomenex Lux Cellulose-3 chiral HPLC column provides reliable enantiomer separation, performing as well or better than CHIRALCEL® OJ® with unique chiral selectivity.
Phenomenex Lux i-Cellulose-5 Chiral HPLC Columns
Phenomenex Lux i-Cellulose-5 chiral HPLC column delivers broad enantioselectivity, strong solvent compatibility, and scalable performance for LC and SFC separations.
Related content
Accelerating Biomarker Discovery and Validation: From Discovery to Clinical Utility
Tu, 23.6.2026
Thermo Fisher Scientific
Deadline for RAFA 2026 Early Registration and Oral Abstract Submission is approaching